CADMATIC
12.1.2023 06:01:40 CET | Business Wire | Press release
Cadmatic is part of a consortium of industrial companies and academic institutions that is leading the EU-funded Smart European Shipbuilding project (SEUS) that was launched 1 January 2023. SEUS is an EU Innovation Action with a focus on computational tools for shipbuilding. The consortium will create a framework for data-driven shipbuilding by developing a new integrated platform that incorporates early and detailed ship design solutions, data management, and collaboration software.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230111005065/en/
Cadmatic is Part of Consortium Leading EU-Funded SEUS Project for Smarter and More Productive Shipbuilding (Photo: Business Wire)
The platform solution aims to slash the time needed for ship engineering by 30% and cut assembly times by an ambitious 20%. It will be built with the best EU shipbuilding expertise provided by the academic and industrial consortium participants and evaluated at two leading European shipyards.
The platform solution will develop novel practices for human-centric knowledge management, data-driven AI design elements, intelligent technology, and an Industry 5.0 concept for shipbuilding. It will also support the growth of a European workforce that is highly skilled in the deployment and use of advanced computational tools in shipbuilding, particularly with respect to the integration of new technologies.
SEUS is part of Horizon Europe, the EU’s flagship research and innovation program with a budget of €95,5 billion. SEUS is funded to the tune of approximately €7 million, of which Cadmatic will receive €1,6 million. Cadmatic is responsible for leading the technical coordination of the four-year-long SEUS project.
The SEUS consortium consists of 8 organizations from 5 countries. The members include highly innovative partners such as well-established shipbuilding solution provider Cadmatic (Finland), PLM data management solution developer Contact Software (Germany), SARC BV (The Netherlands), two shipyards with different profiles in Ulstein Group (Norway) and Astilleros Gondan SA (Spain), and outstanding research institutes: the Norwegian University of Science and Technology (Norway), Turku University (Finland), and NHL Stenden University of Applied Sciences (The Netherlands).
“We are proud to be leading the technical coordination and working alongside the other consortium partners on this ambitious project. It is very exciting to use our shipbuilding expertise to incorporate CAE/CAD/CAM and PLM elements in a single innovative and groundbreaking platform that will take shipbuilding efficiency to the next level,” says Ludmila Seppälä, Business Development Director at Cadmatic.
About Cadmatic
Cadmatic is a leading developer of digital and intelligent 3D design and information management software solutions for the marine, power, process, and construction industries. It empowers engineers to build a brighter future and a better world by making the design, engineering, construction and operation of ships, industrial plants and buildings better, faster and easier. Cadmatic has over 6000 customer organizations in 60 countries.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230111005065/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom